TELA Bio, Inc. (TELA) stock
Close on Nov 13, 2026Market cap $36.82MP/E –Yield –
TELA Bio, Inc. grew revenue 1.5% to $78.18M over the twelve months to Sep 30, 2026. Free cash flow was -$34.39M. At the latest close the market valued the company at $36.82M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $36.82M
- P/E ratio
- –
- Price to sales
- 0.47
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -93.40%
Fundamentals
- Revenue
- $78.18M
- Net income
- -$41.88M
- EPS, diluted
- -$0.74
- Free cash flow
- -$34.39M
- Book value per share
- -$0.43
- Diluted shares
- 58M
Trading
- Next earnings
- Mar 23, 2027 (estimated, after the close)
- Previous close
- $0.86
- Open
- $0.82
- Day's range
- $0.76 – $0.84
- Volume
- 129,176
- Average volume (20 days)
- 148,509
- Beta (5 years)
- 0.62
- 52-week range
- $0.50 – $1.50
- RSI (14 days)
- 42.6
- Volatility (1 year)
- 96.1%
- Relative volume
- 0.67×
- WACC
- 9.9%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | TELA | S&P 500 | Difference | TELA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.0% | -3.0% | −20.0 pts | ||
| 3 months | +21.0% | -2.8% | +23.7 pts | ||
| Year to date | -30.5% | +11.5% | −42.0 pts | ||
| 1 year | -26.1% | +13.5% | −39.6 pts | ||
| 3 years | -81.8% | +77.7% | −159.5 pts | -43.3% | +21.1% |
| 5 years | -93.7% | +72.6% | −166.3 pts | -42.4% | +11.5% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases TELA Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Results
- Results
- Results
About TELA Bio
Surgical & Medical Instruments & Apparatus
The company is a commercial-stage medical technology firm that focuses on developing and commercializing soft-tissue reconstruction products. Its main offerings consist of the OviTex and OviTex PRS lines of reinforced tissue matrices, which integrate minimally processed ovine rumen biologic material with interwoven polymer fibers to support natural tissue remodeling and repair. These devices serve surgical procedures including ventral, inguinal, and hiatal hernia repairs, abdominal wall reconstruction, and plastic and reconstructive surgery. The company also distributes complementary surgical products such as hernia mesh fixation devices. It primarily serves surgeons, hospitals, and healthcare providers, reaching them directly or through national group purchasing organizations and integrated delivery networks.
Company profile, executives and historyTELA Bio stock: common questions
What is TELA Bio's stock price?
TELA closed at $0.82 on Nov 13, 2026, down 4.64% on the day. Over the past 52 weeks it traded between $0.50 and $1.50.
What is TELA Bio's market cap?
TELA Bio was worth $36.82M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is TELA's P/E ratio?
TELA Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.74), so it has no meaningful P/E ratio.
How much revenue does TELA Bio make?
TELA Bio reported revenue of $78.18M for the twelve months to Sep 30, 2026, up 1.5% from a year earlier.
Does TELA Bio pay a dividend?
No. TELA Bio has not paid a cash dividend over the last twelve months.
When does TELA Bio report earnings next?
TELA Bio is expected to report Q4 FY2026 results on Mar 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has TELA stock performed over the past year?
Including dividends, TELA returned -26.1% over the past year, against +13.5% for the S&P 500.
How many TELA shares are sold short?
1M shares were sold short at the latest FINRA report, 2.19% of the float, or 5.1 days of average trading volume.
Who are TELA Bio's competitors?
Companies most similar to TELA Bio by business, industry and size include RCEL, LUNG, XTNT, SI, ANIK.
See a number that looks wrong?